clinical trial · NCT07195682
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Bristol-Myers Squibb·phase1·recruiting·n = 125
Renal Cell CarcinomaBMS-986506
brief summary
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
started
Jan 15, 2026
primary completion
May 3, 2030
completion
Apr 3, 2031
last updated
Jun 9, 2026
official title
A Phase 1/1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol